Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 29 March 2011
Vol. 4, Issue 166, p. eg3
[DOI: 10.1126/scisignal.2002014]

EDITORIAL GUIDES

Focus Issue: Rendering Resistance Futile

Elizabeth M. Adler1* and Nancy R. Gough2

1 Senior Editor of Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, N.W., Washington, DC 20005, USA.
2 Editor of Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, N.W., Washington, DC 20005, USA.

Abstract: In conjunction with the Science special issue on cancer (http://www.sciencemag.org/special/cancer2011/), this issue of Science Signaling focuses on mechanisms whereby cancer cells become resistant to antineoplastic therapy. This issue explores mechanisms whereby cancer cells can become resistant to classical chemotherapy drugs aimed at rapidly proliferating cells or to newer agents that depend on specific inhibition of oncogenic kinases or downstream components of aberrantly activated signaling pathways.

* Corresponding author. E-mail, eadler{at}aaas.org

Citation: E. M. Adler, N. R. Gough, Focus Issue: Rendering Resistance Futile. Sci. Signal. 4, eg3 (2011).

Read the Full Text



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882